- Drug Pipelines
- April 2024
- 50 Pages
Global
From €1433EUR$1,500USD£1,198GBP
- Report
- July 2024
- 100 Pages
Global
From €3581EUR$3,750USD£2,995GBP
- Report
- June 2024
- 200 Pages
Global
From €7593EUR$7,950USD£6,349GBP
- Report
- June 2024
- 200 Pages
Global
From €7593EUR$7,950USD£6,349GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1910EUR$2,000USD£1,597GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1910EUR$2,000USD£1,597GBP
- Report
- July 2024
- 100 Pages
Global
From €3581EUR$3,750USD£2,995GBP
- Report
- July 2022
- 227 Pages
Global
From €7163EUR$7,500USD£5,990GBP
- Report
- July 2022
- 113 Pages
Global
From €3772EUR$3,950USD£3,155GBP
- Report
- January 2022
- 60 Pages
Global
From €3772EUR$3,950USD£3,155GBP
- Report
- January 2022
- 60 Pages
Global
From €3772EUR$3,950USD£3,155GBP
- Report
- August 2024
- 91 Pages
Global
From €3500EUR$3,926USD£3,029GBP

The Burn Drug market is a subset of the Dermatological Drugs market, which focuses on the treatment of skin conditions. Burn Drugs are used to treat burns, which can range from minor to severe. These drugs are typically used to reduce pain, reduce inflammation, and promote healing. They may also be used to prevent infection and reduce scarring. Common Burn Drugs include topical creams, ointments, and gels, as well as oral medications.
Burn Drugs are often used in combination with other treatments, such as dressings, bandages, and physical therapy. In some cases, surgery may be necessary to treat severe burns.
Some companies in the Burn Drug market include GlaxoSmithKline, Johnson & Johnson, Pfizer, and Merck. Other companies include Allergan, Novartis, and Sanofi. Show Less Read more